CoChat

Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Adeno-associated virus (AAV)-mediated CRISPR-Cas9 editing holds promise to treat many diseases. The immune response to bacterial-derived Cas9 has been speculated as a hurdle for AAV-CRISPR therapy. However, immunological consequences of AAV-mediated Cas9 expression have thus far not been thoroughly investigated in large mammals. We evaluate Cas9-specific immune responses in canine models of Duchenne muscular dystrophy (DMD) following intramuscular and intravenous AAV-CRISPR therapy. Treatment results initially in robust dystrophin restoration in affected dogs but also induces muscle inflammation, and Cas9-specific humoral and cytotoxic T-lymphocyte (CTL) responses that are not prevented by the muscle-specific promoter and transient prednisolone immune suppression. In normal dogs, AAV-mediated Cas9 expression induces similar, though milder, immune responses. In contrast, other therapeutic (micro-dystrophin and SERCA2a) and reporter (alkaline phosphatase, AP) vectors result in persistent expression without inducing muscle inflammation. Our results suggest Cas9 immunity may represent a critical barrier for AAV-CRISPR therapy in large mammals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-26830-7

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cytotoxic T-lymphocyte response to intramuscular AAV CRISPR therapy attenuated dystrophin restoration in canine DMD models. a Cas9 and gRNA vectors. b–i AAV CRISPR therapy induced strong immune responses in the LRMD model. b Representative photomicrographs from non-injected and block 3 of the injected muscle. c Dystrophin (+) myofiber quantification. d Cas9 and gRNA vector genome quantification. e Cas9 transcript quantification (for c, d, e, n = 1 for all categories). f Muscle cytokine quantification (N, n = 5; others, n = 1). g Dystrophin and Cas9 western blot. h Serum Cas9 antibody. i Cas9-specific IFN-γ ELISpot assay on PBMCs (for h and i: Naive, n = 11; 6 wks., n = 1). j-p Cytotoxic T-lymphocyte response induced by AAV CRISPR therapy cleared rescued dystrophin in the WCMD model. Muscle was co-injected with an RSV.AP reporter vector. j Representative photomicrographs. k Dystrophin western blot. l Cas9, gRNA and AP vector genome quantification (N, n = 5; 3 and 6 wks., n = 3). m Cas9 and AP transcript (n = 3 for all categories). n Dystrophin (+) myofiber quantification (n = 3 for both). o Serum Cas9 antibody (Naive, n = 14; 3 and 6 wks., n = 1). p Cas9-specific IFN-γ ELISpot assay on PBMCs (n = 1 for all categories). q Representative photomicrographs from affected dogs that were injected with flag-tagged CK8.SERCA2a and CMV.micro-dystrophin (µDys) vectors. Red arrow, FoxP3+ T cells; Yellow arrowhead, FoxP3-negative myonuclei. r, Muscle interleukin-2 (IL-2) and IFN-γ transcript quantification (N, n = 14; n = 3 for each category except n = 1 for µDys 6 wks). Immune cells are stained in dark brown and AP is stained in blue. Numbers (1, 2, 3, 4) in b–g are muscle block numbers. AP, alkaline phosphatase. N, No AAV. N/A, non-applicable. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for h, i, o One-way ANOVA with Tukey’s multiple comparisons for l, m, and r, and Student’s t-test for n. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 1 Cytotoxic T-lymphocyte response to intramuscular AAV CRISPR therapy attenuated dystrophin restoration in canine DMD models. a Cas9 and gRNA vectors. b–i AAV CRISPR therapy induced strong immune responses in the LRMD model. b Representative photomicrographs from non-injected and block 3 of the injected muscle. c Dystrophin (+) myofiber quantification. d Cas9 and gRNA vector genome quantification. e Cas9 transcript quantification (for c, d, e, n = 1 for all categories). f Muscle cytokine quantification (N, n = 5; others, n = 1). g Dystrophin and Cas9 western blot. h Serum Cas9 antibody. i Cas9-specific IFN-γ ELISpot assay on PBMCs (for h and i: Naive, n = 11; 6 wks., n = 1). j-p Cytotoxic T-lymphocyte response induced by AAV CRISPR therapy cleared rescued dystrophin in the WCMD model. Muscle was co-injected with an RSV.AP reporter vector. j Representative photomicrographs. k Dystrophin western blot. l Cas9, gRNA and AP vector genome quantification (N, n = 5; 3 and 6 wks., n = 3). m Cas9 and AP transcript (n = 3 for all categories). n Dystrophin (+) myofiber quantification (n = 3 for both). o Serum Cas9 antibody (Naive, n = 14; 3 and 6 wks., n = 1). p Cas9-specific IFN-γ ELISpot assay on PBMCs (n = 1 for all categories). q Representative photomicrographs from affected dogs that were injected with flag-tagged CK8.SERCA2a and CMV.micro-dystrophin (µDys) vectors. Red arrow, FoxP3+ T cells; Yellow arrowhead, FoxP3-negative myonuclei. r, Muscle interleukin-2 (IL-2) and IFN-γ transcript quantification (N, n = 14; n = 3 for each category except n = 1 for µDys 6 wks). Immune cells are stained in dark brown and AP is stained in blue. Numbers (1, 2, 3, 4) in b–g are muscle block numbers. AP, alkaline phosphatase. N, No AAV. N/A, non-applicable. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for h, i, o One-way ANOVA with Tukey’s multiple comparisons for l, m, and r, and Student’s t-test for n. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.CC BY · PubMed Central
Fig. 2 AAV-mediated Cas9 expression induced humoral and cellular immune responses in normal dogs following intramuscular injection. a–e 1-week-old normal dogs were either co-injected with AAV.CK8.SpCas9 and AAV.RSV.AP or injected with AAV.RSV.AP only. a Representative HE, AP, CD4, and CD8 stainings. b Cas9, and AP vector genome quantification (N, n = 5; others, n = 3). c Serum Cas9 antibody (Naive, n = 8; 6wks., n = 1). d Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 3). e Muscle cytokine transcript quantification (Naive, n = 8; others, n = 3). f-j Similar to a-e except 1-m-old dogs were injected. f Representative HE, AP, CD4, and CD8 stainings. Arrowhead, T-cell infiltration wiped out AP expression. g Cas9 and AP vector genome quantification (N, n = 4; others, n = 3). h Serum Cas9 antibody (N, n = 12; 6wks., n = 1). i Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 1). j Muscle cytokine transcript quantification (N, n = 14; others, n = 3). k–p Similar to a-e except adult dogs were injected with either AAV.CK8.SpCas9 or AAV.RSV.AP. k Representative HE, AP, CD8, and granzyme B stainings. The boxed region was magnified. Yellow arrowhead, a dying myofiber lost dystrophin expression and infiltrated with CD8+ and granzyme B+ T cells. l CD8+ T-cell quantification (n = 3 for all categories). m Dystrophin and Cas9 western blot. n Serum Cas9 antibody (Naive, n = 27; others, n = 3). o Cas9 ELISpot assay on lymphocytes (Naive, n = 6; others, n = 3). p Muscle cytokine transcript quantification from adult dogs (N, n = 12; others, n = 3). Immune cells are stained in dark brown, and AP is stained in blue. AP, alkaline phosphatase. N, No AAV. N/A, non-applicable. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for c, h, i, One-way ANOVA with Tukey’s multiple comparisons for b, e, g, j, l, and n-p and Student’s t-test for d. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 2 AAV-mediated Cas9 expression induced humoral and cellular immune responses in normal dogs following intramuscular injection. a–e 1-week-old normal dogs were either co-injected with AAV.CK8.SpCas9 and AAV.RSV.AP or injected with AAV.RSV.AP only. a Representative HE, AP, CD4, and CD8 stainings. b Cas9, and AP vector genome quantification (N, n = 5; others, n = 3). c Serum Cas9 antibody (Naive, n = 8; 6wks., n = 1). d Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 3). e Muscle cytokine transcript quantification (Naive, n = 8; others, n = 3). f-j Similar to a-e except 1-m-old dogs were injected. f Representative HE, AP, CD4, and CD8 stainings. Arrowhead, T-cell infiltration wiped out AP expression. g Cas9 and AP vector genome quantification (N, n = 4; others, n = 3). h Serum Cas9 antibody (N, n = 12; 6wks., n = 1). i Cas9 ELISpot assay on lymphocytes (Naive, n = 5; 6wks., n = 1). j Muscle cytokine transcript quantification (N, n = 14; others, n = 3). k–p Similar to a-e except adult dogs were injected with either AAV.CK8.SpCas9 or AAV.RSV.AP. k Representative HE, AP, CD8, and granzyme B stainings. The boxed region was magnified. Yellow arrowhead, a dying myofiber lost dystrophin expression and infiltrated with CD8+ and granzyme B+ T cells. l CD8+ T-cell quantification (n = 3 for all categories). m Dystrophin and Cas9 western blot. n Serum Cas9 antibody (Naive, n = 27; others, n = 3). o Cas9 ELISpot assay on lymphocytes (Naive, n = 6; others, n = 3). p Muscle cytokine transcript quantification from adult dogs (N, n = 12; others, n = 3). Immune cells are stained in dark brown, and AP is stained in blue. AP, alkaline phosphatase. N, No AAV. N/A, non-applicable. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for c, h, i, One-way ANOVA with Tukey’s multiple comparisons for b, e, g, j, l, and n-p and Student’s t-test for d. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.CC BY · PubMed Central
Fig. 3 Systemic AAV CRISPR therapy induced humoral and cellular immune responses against Cas9. a Representative HE, dystrophin, CD4, and CD8 stainings from biopsy. b, Representative dystrophin and CD8 stainings from necropsied muscles. c Representative HE, dystrophin, CD8, and granzyme B staining from a necropsied muscle. d Cas9 and gRNA vector genome quantification (N, n = 7; 3wks., n = 1; 6wks., n = 11). e Cas9 transcript quantification (N, n = 7; 3wks., n = 1; 6wks., n = 11). f Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 10 weeks after birth, respectively; dog#1, n = 1 for 0, 4–10 weeks after birth). g PBMC IFN-γ ELISPOT against Cas9 (N, n = 11; dog #1 n = 1 for all-time points). h Representative HE, dystrophin, CD4, and CD8 staining from biopsy. i Representative dystrophin and CD8 staining from necropsied muscles. j Representative HE, dystrophin, CD8, and granzyme B stainings from a necropsied muscle. k Cas9 and gRNA vector genome quantification (N, n = 7; 3wks., n = 1; 6wks., n = 18). l Cas9 transcript quantification (N, n = 7, 3wks., n = 1; 6wks., n = 18). m Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for 0, 4–16 weeks after birth). n Cas9 specific IFN-γ ELISpot assay on PBMCs (N, n = 11; dog #1 n = 1 for all-time points). o Representative HE, dystrophin, CD4 and CD8 staining from the control dog that received the micro-dystrophin vector. p Muscle cytokine transcript quantification from all three dogs (N, n = 7;dog#1, 3wks. n = 1, 6wks. n = 11; dog#2, 3wks. n = 1, 12wks. n = 18; μDys injected dog, 6wks. n = 1, 24wks. n = 1). Immune cells are stained in dark brown. Arrow, a granzyme B-positive T cell. N, No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford–Howell test for d–g and k–n, One-way ANOVA with Tukey’s multiple comparisons for p. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 3 Systemic AAV CRISPR therapy induced humoral and cellular immune responses against Cas9. a Representative HE, dystrophin, CD4, and CD8 stainings from biopsy. b, Representative dystrophin and CD8 stainings from necropsied muscles. c Representative HE, dystrophin, CD8, and granzyme B staining from a necropsied muscle. d Cas9 and gRNA vector genome quantification (N, n = 7; 3wks., n = 1; 6wks., n = 11). e Cas9 transcript quantification (N, n = 7; 3wks., n = 1; 6wks., n = 11). f Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 10 weeks after birth, respectively; dog#1, n = 1 for 0, 4–10 weeks after birth). g PBMC IFN-γ ELISPOT against Cas9 (N, n = 11; dog #1 n = 1 for all-time points). h Representative HE, dystrophin, CD4, and CD8 staining from biopsy. i Representative dystrophin and CD8 staining from necropsied muscles. j Representative HE, dystrophin, CD8, and granzyme B stainings from a necropsied muscle. k Cas9 and gRNA vector genome quantification (N, n = 7; 3wks., n = 1; 6wks., n = 18). l Cas9 transcript quantification (N, n = 7, 3wks., n = 1; 6wks., n = 18). m Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for 0, 4–16 weeks after birth). n Cas9 specific IFN-γ ELISpot assay on PBMCs (N, n = 11; dog #1 n = 1 for all-time points). o Representative HE, dystrophin, CD4 and CD8 staining from the control dog that received the micro-dystrophin vector. p Muscle cytokine transcript quantification from all three dogs (N, n = 7;dog#1, 3wks. n = 1, 6wks. n = 11; dog#2, 3wks. n = 1, 12wks. n = 18; μDys injected dog, 6wks. n = 1, 24wks. n = 1). Immune cells are stained in dark brown. Arrow, a granzyme B-positive T cell. N, No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford–Howell test for d–g and k–n, One-way ANOVA with Tukey’s multiple comparisons for p. See source data file for the exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.CC BY · PubMed Central
Fig. 4 Systemic AAV.CK8.Cas9 injection in 1-m-old normal dogs induced humoral and cellular immune responses against Cas9. a Representative HE, AP CD4, and CD8 stainings. b Cas9 and AP vector genome quantification (N, n = 7; others, n = 1). c Cas9 and AP transcript quantification (N, n = 7; others, n = 1). d AP + myofiber quantification (n = 1 in all categories). e Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#1, n = 1 for all-time points). f Cas9-specific IFN-γ ELISpot assay on PBMCs (N, n = 11; dog #1 n = 1 for all-time points). g Representative HE, AP, CD4, and CD8 staining. h Cas9 and AP vector genome quantification (N, n = 7; others, n = 1). i Cas9 and AP transcript quantification (in both panels: N, n = 7; each other group, n = 1). j AP + myofiber quantification (n = 1 in each group). k Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for all time points). l, PBMC IFN-γ ELISpot against Cas9 (N, n = 11; dog #1 n = 1 for all time points). m Representative HE, AP, CD4, and CD8 stainings. n AP vector genome quantification (N, n = 7; others, n = 1). o AP transcript quantification (N, n = 7; others, n = 1). p Muscle cytokine transcript quantification from all 3 dogs at the indicated time points post-injection (N, n = 14; dog#1, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog#2, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog injected with AP vector only, 6wks. n = 1, 52 wks. n = 1). AP, alkaline phosphatase. N, No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for b, c, e, f, h, i, k, l, n, o, and One-way ANOVA with Tukey’s multiple comparisons for p. See source data file for exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 4 Systemic AAV.CK8.Cas9 injection in 1-m-old normal dogs induced humoral and cellular immune responses against Cas9. a Representative HE, AP CD4, and CD8 stainings. b Cas9 and AP vector genome quantification (N, n = 7; others, n = 1). c Cas9 and AP transcript quantification (N, n = 7; others, n = 1). d AP + myofiber quantification (n = 1 in all categories). e Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#1, n = 1 for all-time points). f Cas9-specific IFN-γ ELISpot assay on PBMCs (N, n = 11; dog #1 n = 1 for all-time points). g Representative HE, AP, CD4, and CD8 staining. h Cas9 and AP vector genome quantification (N, n = 7; others, n = 1). i Cas9 and AP transcript quantification (in both panels: N, n = 7; each other group, n = 1). j AP + myofiber quantification (n = 1 in each group). k Serum Cas9 antibody (N, n = 16, 8, 9, 11, 12, 23, 11 and 18 for 0, 1, 2, 3, 4, 6, 8, and 16 weeks after birth, respectively; dog#2, n = 1 for all time points). l, PBMC IFN-γ ELISpot against Cas9 (N, n = 11; dog #1 n = 1 for all time points). m Representative HE, AP, CD4, and CD8 stainings. n AP vector genome quantification (N, n = 7; others, n = 1). o AP transcript quantification (N, n = 7; others, n = 1). p Muscle cytokine transcript quantification from all 3 dogs at the indicated time points post-injection (N, n = 14; dog#1, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog#2, 3wks. n = 1, 6wks. n = 1, 12wks. n = 1; dog injected with AP vector only, 6wks. n = 1, 52 wks. n = 1). AP, alkaline phosphatase. N, No AAV. wks., weeks post-injection. Data are mean ± SEM. Statistical analysis was performed using Crawford-Howell test for b, c, e, f, h, i, k, l, n, o, and One-way ANOVA with Tukey’s multiple comparisons for p. See source data file for exact p-value. *p < 0.05; **p < 0.01; ***p < 0.001.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 187

Metadata

Authors
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., Nelson, C. E., Metzger, S., Han, J., Louderman, J. A., Schmidt, F., Feng, F., Grimm, D., Smith, B. F., Yao, G., Yang, N. N., Gersbach, C. A., Chen, S.-J., Herzog, R. W., & Duan, D.
Affiliations
  • National Institutes of Health (US)
  • Indiana University Indianapolis (US)
  • University of Missouri (US)
  • Duke University (US)
  • Heidelberg University (DE)
  • Auburn University (US)
Corresponding author
Duan, Dongsheng
Venue
Nature Communications
Published
2021-11-24
Volume
12
Issue
1
Pages
6769-6769
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3216412686
Cited by
175
References
57
Citations by year
2026: 28 · 2025: 39 · 2024: 37 · 2023: 36 · 2022: 31 · 2021: 4
FWCI
15.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM008396)
  • University of Missouri Life Science Fellowship
  • U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS-90634)
  • U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR-70517)
  • Parent Project Muscular Dystrophy (no number)
  • U.S. Department of Defense (MD150133)
  • Hope for Javier, Jackson Freel DMD Research Fund, Team Joseph, Charley’s Fund, Zubin’s Wish, Jett Foundation, Cure Duchenne, and Destroy Duchenne
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
Duchenne muscular dystrophy, canine model, dystrophin restoration, muscle inflammation, cytotoxic T lymphocytes, humoral immune response, muscle-specific promoter, microdystrophin, SERCA2a, alkaline phosphatase reporter
MeSH terms
Gene Editing, Dependovirus, Animals, Disease Models, Animal, Dogs, Genetic Vectors, Humans, Genetic Therapy, Dystrophin, Genes, Reporter, Muscle, Skeletal, Muscular Dystrophy, Duchenne, Sarcoplasmic Reticulum Calcium-Transporting ATPases, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. https://app.cochat.ai/papers/10.1038/s41467-021-26830-7
The paper
Hakim, C. H., Kumar, S. R. P., Pérez-López, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., Nelson, C. E., Metzger, S., Han, J., Louderman, J. A., Schmidt, F., Feng, F., Grimm, D., Smith, B. F., Yao, G., . . . Duan, D. (2021). Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nature Communications. https://doi.org/10.1038/s41467-021-26830-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.